“A story has been woven and re-told endlessly about faulty technology and even an absence of technology at Theranos. Nothing could be farther from the truth. The technology at Theranos was real, innovative and had the potential to revolutionize the in-vitro diagnostic sector for the better.”

- Fabrizio Bonanni, former board member of Theranos. Page 6

“Near the end, we had an independent third party consultant evaluate the business case for the machine as it actually was and they concluded it would generate a billion dollars in revenue in the first 10 years. None the less, the investors decided to force bankruptcy… The technology was brilliant.”

- Donald L. Tschirdhart, former Theranos employee, page 11

“There were working prototypes of several of the internal subsytems of the system capable of generating accurate clinical results… with funding and additional time, it was highly likely that a Theranos POC platform would have been completed and commercialized…During my tenure I saw a woman making challenging, difficult, and thoughtful decisions, adding skilled resources and making every effort to deliver to the market a new diagnostic product and a return to the investors… She acknowledged the technical shortcomings of early days of the company and was making a sincere effort to deliver a quality product for all involved.”

- Susan Evans, former Theranos Scientific Advisory Board, page 5

"Following the Wall Street Journal articles, Ms. Holmes made a concerted effort to achieve credibility in the scientific community. She did this in numerous ways. She had outside experts spend time at the Theranos facility. She allowed those experts to talk to anyone. She allowed those experts to inspect the hardware, and make suggestions. I had personal experience, at several of the visits, and Ms. Holmes was totally transparent with everyone who came to review the technology."

"Ms. Holmes was not interested in money."

"She could have taken her personal patents and profited from them. Instead, she put up her patents as collateral for Theranos to borrow $100 million, in the hope of bringing the company to a viable commercial stage."

- William Foege, board member, page 6

“She is a genuinely good person with a good heart who relied on others for advice and guidance, but she often received very bad guidance which I believe is the root cause of the issues you are familiar with. She always put the interests of the company ahead of her own. She took a meager salary and never sold a share of her stock. For all her efforts, after 15 years at Theranos she was virtually penniless… She made mistakes, but I believe many of her mistakes were the result of bad advice, and were not motivated by any desire on her part to deceive or defraud anyone.”

- Daniel Warmenhoven, former board member of Theranos, page 7

"Despite widespread assertions on social media, this was never about greed or personal enrichment. She lived quite modestly until moving in with Sunny. Because she believed in the company and its future, she took most of her compensation in the form of company stock. Then, as the company was imploding, she voluntary donated the $30 million D&O insurance settlement back to Theranos, buying the company some more time as they tried to succeed."

“In the press and social media, she is portrayed as a schemer who created a criminal enterprise in order to bilk investors. This is a completely false narrative.”

“Its patents, once valued at over a billion dollars, were ultimately sold for $100 million in a fire sale.”

- James Orr, Theranos investor, page 2

“In the 2015 timeframe, Ms. Holmes was offered the opportunity to sell hundreds of millions of dollars of her stock holdings in Theranos. She turned down that opportunity because she felt that she should not profit until all her investors had returned their investment profitably. It is beyond reasonable judgement that someone intending to commit fraud would decline an opportunity to cash in hundreds of millions of dollars from an investor anxiously wanting to invest in Theranos.”

“The prosecutors have followed essentially the script of the multiple articles from the Wall Street Journal, and the subsequent book and movie based thereon. That story paints Ms. Holmes as a villain in the long tradition of journalistic zeal to find, and sell, scandal. That story is based largely on conjecture and unverified assumptions. However at the same time, the Securities and Exchange Commission (“SEC”) conducted a nearly 18-month investigation of Theranos and Ms. Holmes… The SEC made no finding of guilt on behalf of Ms. Holmes and accepted a settlement of five-hundred thousand dollars…”

“Ms. Holmes is a very good person. Kind, smart and a positive contributor to society.”

“Theranos was not, and is not, the house of cards the prosecution painted it to be. An unrelated financial institution paid in excess of $100 million to purchase the numerous patents which Ms. Holmes and her team created and expressed a view that they may be worth over $1 billion dollars. That is not a house of cards.”

- David Sokol, advisor, page 3

"Despite her current situation, I believe Elizabeth Holmes to be an honorable individual, a valuable member of the community, and a good human being.”

“Our leadership under Elizabeth was second to none.”

“Elizabeth was there for every employee, especially when Theranos closed. Elizabeth made it a point to be there and show significant support during a sudden and arduous job search. Theranos provided every employee with a separation package, resume support services, and job placement before it closed its doors.”

- Bienvenido Morel, employee, page 10

"The Elizabeth Holmes that I encountered was a genuine and compassionate individual who cared about the lives of those with whom she came into contact."

"Based upon my personal contact with Ms. Holmes, I cannot conceive for a moment that she poses any future threat to society. In fact, I firmly believe the opposite to be true. I believe she has a great deal to offer to potential entrepreneurs based upon her expertise and experience."

- Jeffrey S. Lloyd, advisor, page 189